羟考酮缓释胶囊Xtampza ER(oxycodone)是一款防滥用缓释阿片类止痛药,于2016年4月获美国FDA批准上市。Xtampza ER是采用Collegium专有DETERx防滥用技术开发的首个产品,能有效解决常用给药方法造成的滥用问题。Xtampza ER的标签信息包括支持通过咀嚼、粉碎然后与软的食物或水中直接口服,或通过胃造瘘口和鼻饲管给药。
研发公司:Collegium Pharmaceutical公司
Xtampza ER (Oxycodone Extended-release Capsules)
XTAMPZA ER
Narcotic analgesics Only 4 drugs may be compared at once
Generic Name and Formulations:
Oxycodone 9mg, 13.5mg, 18mg, 27mg, 36mg; ext-rel caps.
Company:
Collegium Pharmaceutical, Inc.
Select therapeutic use: Narcotic analgesics
Indications for XTAMPZA ER:
Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Limitations Of use:
Not for use as an as-needed (prn) analgesic. Use only if alternative treatment options (eg, non-opioid analgesics, immediate-release opioids) are ineffective, not tolerated, or otherwise inadequate to provide sufficient management of pain.
Adult:
Use lowest effective dose for shortest duration. Take with food. Swallow whole or may sprinkle capsule contents on soft foods or into a cup. May also give through gastrostomy or NG feeding tube. Individualize. Usually given on a 12-hour schedule. ≥18yrs: Opioid-naive or opioid non-tolerant: initially 9mg every 12hrs. May adjust dose at 1–2 day intervals. Max dose 288mg/day. Hepatic impairment: initiate at ⅓ to ½ the usual starting dose and titrate slowly; use alternative analgesic if <9mg required. Use a single dose >36mg, or a total daily dose >72mg in opioid-tolerant patients only. Conversion from other opioids: see full labeling. Concomitant use or discontinuation of CYP3A4 inhibitors or inducers: monitor closely and consider dose adjustments (see full labeling).
Children:
<18yrs: not established.
Contraindications:
Significant respiratory depression. Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment. Known or suspected GI obstruction, including paralytic ileus.
Warnings/Precautions:
Life-threatening respiratory depression; monitor within first 24–72hrs of initiating therapy and following dose increases. Accidental exposure may cause fatal overdose (esp. in children). COPD, cor pulmonale, decreased respiratory reserve, hypoxia, hypercapnia, or pre-existing respiratory depression; monitor and consider non-opioid analgesics. Abuse potential (monitor). Adrenal insufficiency. Head injury. Increased intracranial pressure, brain tumors; monitor. Seizure disorders. CNS depression. Impaired consciousness, coma, shock; avoid. Biliary tract disease. Acute pancreatitis. Drug abusers. Renal or hepatic impairment. Reevaluate periodically. Avoid abrupt cessation. Elderly. Cachectic. Debilitated. Pregnancy; potential neonatal opioid withdrawal syndrome during prolonged use. Labor & delivery, nursing mothers: not recommended.
Interactions:
Increased risk of hypotension, respiratory depression, sedation with benzodiazepines or other CNS depressants (eg, non-benzodiazepine sedatives/hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, muscle relaxants, antipsychotics, alcohol, other opioids); reserve concomitant use in those for whom alternative options are inadequate; limit dosages/durations to minimum required; monitor. During or within 14 days of MAOIs: not recommended. Risk of serotonin syndrome with serotonergic drugs (eg, SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, mirtazapine, trazodone, tramadol, MAOIs, linezolid, IV methylene blue); monitor and discontinue if suspected. Avoid concomitant mixed agonist/antagonist opioids (eg, butorphanol, nalbuphine, pentazocine) or partial agonist (eg, buprenorphine); may reduce effects and precipitate withdrawal symptoms. Potentiated by CYP3A4 inhibitors (eg, macrolides, azole antifungals, protease inhibitors). Antagonized by CYP3A4 inducers (eg, rifampin, carbamazepine, phenytoin). May antagonize diuretics; monitor. Paralytic ileus may occur with anticholinergics. May increase serum amylase.
Pharmacological Class:
Opioid agonist.
Adverse Reactions:
Nausea, headache, constipation, somnolence, pruritus, vomiting, dizziness; respiratory depression, severe hypotension, syncope.
REMS:
YES
Generic Availability:
NO
How Supplied:
ER caps—100
当前位置:药品说明书与价格首页 >> 综合药讯 >> Xtampza ER (Oxycodone Extended-release Capsules)
Xtampza ER (Oxycodone Extended-release Capsules)简介:羟考酮缓释胶囊Xtampza ER(oxycodone)是一款防滥用缓释阿片类止痛药,于2016年4月获美国FDA批准上市。Xtampza ER是采用Collegium专有DETERx防滥用技术开发的首个产品,能有效解决常用给药方法造成的滥用问题。 ... 责任编辑:p53 |
最新文章更多推荐文章更多热点文章更多
|